MEDIA

Precision medicine manufacturer General Biologicals Corporation (hereinafter referred to as “GBC”, Taiwan stock code: 4117) participated in the 2022 BIO Asia-Taiwan Asia Biotechnology Exhibition from July 28 to July 31, and exhibited CellBio™ circulating tumor Cell (CTC) detection system products, through CellBio™, can effectively identify circulating tumor cells (CTC) in the blood, can effectively monitor whether the tumor has metastasized, and assist physicians to track patients’ health and treatment results. In recent years, GBC has continued to actively promote liquid biopsy applications and the expansion of its business network with hospitals in Taiwan and other different countries.

GBC said that the Group has fully deployed the CellBio™ cancer screening technology platform. Through the CellBio™ circulating tumor cell (CTC) detection system, the products have excellent characteristics such as safety, rapidity, precision, automation and non-invasiveness, and have more than 1,000 clinical trials, using the method of physical filter membrane and fluorescent staining. According to the size of cells and different surface markers, CTCs are separated and recovered from human blood samples. The collection and testing process can monitor the number of circulating tumor cells in the blood, and effectively captures more than 90% of cancer cells. The operation time can be completed in less than 60 minutes. It can perform more than 300 sample tests per day. At present, GBC has started to develop fully automated equipment that can perform more than 1,000 tests a day, effectively and quickly process samples, and improve the quality of cancer “screening and monitoring”, “diagnosis” and “post-surgery”.